A Gram-stain-positive, strictly anaerobic, endospore-forming and rod-shaped (0.6-0.8×2.7-13.1 µm) bacterium, designated as 5 N-1, was isolated from a yellow water sample collected from the manufacturing process of Nongxiangxing baijiu in the Yibin region of Sichuan, PR China. Growth occurred at 15-40 °C (optimum growth at 37 °C), at pH 6.0-9.0 (optimum growth at pH 7.0) and in NaCl concentrations of 0-1 % (w/v) and ethanol concentrations of 0-2 % (v/v). The major fatty acids in strain 5 N-1 were C, C and C. The polar lipids were diphosphatidylglycerol, phosphatidylglycerol, phosphatidylethanolamine, four unidentified aminophospholipids and one unidentified lipid. Phylogenetic analysis of its 16S rRNA gene sequence indicated that strain 5 N-1 was most closely related to YB-6 (97.70 %) and DSM 12992 (97.56 %). The average nucleotide identity and digital DNA‒DNA hybridization values between strain 5 N-1 and the above two type strains were 80.89 and 80.05 % and 25.80 and 25.30 %, respectively, which were all below the species thresholds. The genome size of strain 5 N-1 was 3.5 Mbp and the DNA G+C content was 27.5 mol%. Based on the results of phenotypic and genotypic analyses, strain 5 N-1 represents a novel species of the genus , for which the name sp. nov. is proposed. The type strain is 5 N-1 (=CICC 24886=JCM 35355).
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1099/ijsem.0.006420 | DOI Listing |
Clin Microbiol Infect
January 2025
Public Health Wales Microbiology, University Hospital of Wales, Heath Park, Cardiff, UK.
Objectives: Explore the presence, or absence, of virulence genes and the phylogeny of a multi-decade UK collection of clinical and reference Fusobacterium necrophorum isolates.
Methods: Three hundred and eighty-five F. necrophorum strains (1982-2019) were recovered from storage (-80°C).
Int J Mol Sci
December 2024
Department of Microbiology, Faculty of Pharmaceutical Sciences, Medical University of Silesia, Jagiellońska 4, 41-200 Sosnowiec, Poland.
The presented study investigated the possibility of using the MC5 strain, isolated from raw sewage by the enrichment culture method, in the bioremediation of soil contaminated with selected NSAIDs, i.e., ibuprofen (IBF), diclofenac (DCF), and naproxen (NPX), using the bioaugmentation technique.
View Article and Find Full Text PDFMaterials (Basel)
December 2024
Department of Physics, Gachon University, Seongnam 13120, Republic of Korea.
MXenes, two-dimensional (2D) transition metal carbides and nitrides, have shown promise in a variety of applications. The use of MXenes in active electronic devices is restricted to electrode materials due to their metallic nature. However, MXenes can be modified to be semiconducting and can be used for next-generation channel materials.
View Article and Find Full Text PDFScience
January 2025
Department of Geoscience, University of Wisconsin-Madison, Madison, WI, USA.
Accurately modeling the deformation of temperate glacier ice, which is at its pressure-melting temperature and contains liquid water at grain boundaries, is essential for predicting ice sheet discharge to the ocean and associated sea-level rise. Central to such modeling is Glen's flow law, in which strain rate depends on stress raised to a power of = 3 to 4. In sharp contrast to this nonlinearity, we found by conducting large-scale, shear-deformation experiments that temperate ice is linear-viscous ( 1.
View Article and Find Full Text PDFAntibiotics (Basel)
December 2024
Microbiology Laboratory, Bicêtre University Hospital, AP-HP Paris Saclay University, 94270 Le Kremlin-Bicêtre, France.
Background: Meropenem-vaborbactam (MEM-VAB) is a novel carbapenem-beta-lactamase-inhibitor combination that demonstrates activity against carbapenem-resistant (CR) Gram-negative bacteria, and more specifically KPC-producers, since vaborbactam is an effective inhibitor of KPC enzymes in vitro. This study aimed to describe the initial uses and efficacy of MEM-VAB for compassionate treatment during the first 21 months following its early access in France.
Method: A national multicenter retrospective study was conducted, including all patients who received at least one dose of MEM-VAB between 20 July 2020, and 5 April 2022.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!